JP2017530155A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017530155A5 JP2017530155A5 JP2017517713A JP2017517713A JP2017530155A5 JP 2017530155 A5 JP2017530155 A5 JP 2017530155A5 JP 2017517713 A JP2017517713 A JP 2017517713A JP 2017517713 A JP2017517713 A JP 2017517713A JP 2017530155 A5 JP2017530155 A5 JP 2017530155A5
- Authority
- JP
- Japan
- Prior art keywords
- methyloxy
- triazolo
- chlorophenyl
- methyl
- ethylacetamide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- GRVDJDISBSALJP-UHFFFAOYSA-N methyloxidanyl Chemical group [O]C GRVDJDISBSALJP-UHFFFAOYSA-N 0.000 claims description 21
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims description 21
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 claims description 14
- 229940077388 benzenesulfonate Drugs 0.000 claims description 14
- 239000007787 solid Substances 0.000 claims description 13
- 239000008194 pharmaceutical composition Substances 0.000 claims description 10
- 201000010099 disease Diseases 0.000 claims description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 9
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 6
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 6
- 238000000634 powder X-ray diffraction Methods 0.000 claims description 6
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical class OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 claims description 5
- 229940125763 bromodomain inhibitor Drugs 0.000 claims description 5
- 229940092714 benzenesulfonic acid Drugs 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 4
- 238000000371 solid-state nuclear magnetic resonance spectroscopy Methods 0.000 claims description 4
- 239000012453 solvate Substances 0.000 claims description 4
- 238000001228 spectrum Methods 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 3
- 239000000126 substance Substances 0.000 claims description 3
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical group C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 2
- 206010028980 Neoplasm Diseases 0.000 claims description 2
- 239000013543 active substance Substances 0.000 claims description 2
- 230000001154 acute effect Effects 0.000 claims description 2
- 230000001363 autoimmune Effects 0.000 claims description 2
- 201000011510 cancer Diseases 0.000 claims description 2
- 230000001684 chronic effect Effects 0.000 claims description 2
- 229960000913 crospovidone Drugs 0.000 claims description 2
- 230000004968 inflammatory condition Effects 0.000 claims description 2
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims description 2
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims description 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 229940127557 pharmaceutical product Drugs 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 239000002274 desiccant Substances 0.000 description 4
- 239000012535 impurity Substances 0.000 description 4
- 239000002253 acid Substances 0.000 description 1
- 125000000068 chlorophenyl group Chemical group 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462058753P | 2014-10-02 | 2014-10-02 | |
| US62/058,753 | 2014-10-02 | ||
| PCT/EP2015/072515 WO2016050821A1 (en) | 2014-10-02 | 2015-09-30 | Compound |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017530155A JP2017530155A (ja) | 2017-10-12 |
| JP2017530155A5 true JP2017530155A5 (enExample) | 2018-01-11 |
Family
ID=54238438
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017517713A Pending JP2017530155A (ja) | 2014-10-02 | 2015-09-30 | 化合物 |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US9975901B2 (enExample) |
| EP (1) | EP3201199A1 (enExample) |
| JP (1) | JP2017530155A (enExample) |
| KR (1) | KR20170055549A (enExample) |
| CN (1) | CN106715439A (enExample) |
| AU (1) | AU2015326910B2 (enExample) |
| BR (1) | BR112017006342A2 (enExample) |
| CA (1) | CA2960090A1 (enExample) |
| RU (1) | RU2697393C2 (enExample) |
| WO (1) | WO2016050821A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102438072B1 (ko) | 2012-01-12 | 2022-08-31 | 예일 유니버시티 | E3 유비퀴틴 리가아제에 의한 표적 단백질 및 다른 폴리펩티드의 증진된 분해를 위한 화합물 및 방법 |
| US20180228907A1 (en) | 2014-04-14 | 2018-08-16 | Arvinas, Inc. | Cereblon ligands and bifunctional compounds comprising the same |
| RU2745999C1 (ru) * | 2014-12-05 | 2021-04-05 | Х. Ли Моффитт Кэнсер Сентер Энд Рисёч Инститьют, Инк. | Ингибитор бромодомена в качестве адъюванта в противоопухолевой иммунотерапии |
| AU2016232705C1 (en) | 2015-03-18 | 2021-06-17 | Arvinas, Inc. | Compounds and methods for the enhanced degradation of targeted proteins |
| EP3319944A4 (en) | 2015-07-10 | 2019-04-24 | Arvinas, Inc. | MDM2-BASED MODULATORS OF PROTEOLYSIS AND RELATED USE METHODS |
| EP3337476A4 (en) | 2015-08-19 | 2019-09-04 | Arvinas, Inc. | Compounds and methods for the targeted degradation of bromodomain-containing proteins |
| US20170281784A1 (en) | 2016-04-05 | 2017-10-05 | Arvinas, Inc. | Protein-protein interaction inducing technology |
| RU2019117356A (ru) | 2016-11-10 | 2020-12-10 | Лосинь Фармасьютикал (Шанхай) Ко., Лтд. | Азотсодержащее макроциклическое соединение, способ его получения, фармацевтическая композиция и применение |
| IL319363A (en) | 2017-01-31 | 2025-05-01 | Arvinas Operations Inc | Cervalon ligands and bifunctional compounds containing them |
| JP2021512153A (ja) | 2018-01-26 | 2021-05-13 | イエール ユニバーシティ | タンパク質分解のイミド系モジュレーターおよび使用方法 |
| CA3095912A1 (en) | 2018-04-13 | 2019-10-17 | Arvinas Operations, Inc. | Cereblon ligands and bifunctional compounds comprising the same |
| WO2021127443A1 (en) | 2019-12-19 | 2021-06-24 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of androgen receptor |
| CN111533745A (zh) * | 2020-05-20 | 2020-08-14 | 成都药明康德新药开发有限公司 | 叔丁基-3-(氨基甲基)二氢-5h-三唑并二氮杂卓-8(9h)-甲酸基酯制法 |
| WO2025049555A1 (en) | 2023-08-31 | 2025-03-06 | Oerth Bio Llc | Compositions and methods for targeted inhibition and degradation of proteins in an insect cell |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL330635A1 (en) * | 1996-06-12 | 1999-05-24 | Japan Tobacco Inc | Inhibitor of cytokin production, triazepin compound and intermediate compounds used for obtaining the last mentioned one |
| CN101910182B (zh) * | 2007-12-28 | 2013-07-17 | 田边三菱制药株式会社 | 抗癌剂 |
| AU2010317096B2 (en) * | 2009-11-05 | 2015-03-26 | Glaxosmithkline Llc | Benzodiazepine bromodomain inhibitor |
| CA2779355C (en) * | 2009-11-05 | 2018-01-16 | Glaxosmithkline Llc | Benzodiazepine bromodomain inhibitor |
| GB201106743D0 (en) * | 2011-04-21 | 2011-06-01 | Glaxosmithkline Llc | Novel compounds |
| PT2773354T (pt) * | 2011-11-01 | 2019-07-17 | Resverlogix Corp | Formulações orais de libertação imediata para quinazolinonas substituídas |
| US9492460B2 (en) * | 2013-02-27 | 2016-11-15 | Bristol-Myers Squibb Company | Carbazole compounds useful as bromodomain inhibitors |
-
2015
- 2015-09-30 KR KR1020177010949A patent/KR20170055549A/ko not_active Withdrawn
- 2015-09-30 AU AU2015326910A patent/AU2015326910B2/en not_active Ceased
- 2015-09-30 RU RU2017107760A patent/RU2697393C2/ru active
- 2015-09-30 BR BR112017006342A patent/BR112017006342A2/pt not_active Application Discontinuation
- 2015-09-30 CA CA2960090A patent/CA2960090A1/en not_active Abandoned
- 2015-09-30 CN CN201580053064.0A patent/CN106715439A/zh active Pending
- 2015-09-30 EP EP15771952.7A patent/EP3201199A1/en not_active Withdrawn
- 2015-09-30 JP JP2017517713A patent/JP2017530155A/ja active Pending
- 2015-09-30 US US15/515,683 patent/US9975901B2/en not_active Expired - Fee Related
- 2015-09-30 WO PCT/EP2015/072515 patent/WO2016050821A1/en not_active Ceased
-
2018
- 2018-04-18 US US15/955,857 patent/US10450319B2/en not_active Expired - Fee Related
-
2019
- 2019-09-05 US US16/561,208 patent/US20190389870A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102011641B1 (ko) | 치환된 퀴나졸리논을 위한 경구 즉시 방출 제형 | |
| RU2017107760A (ru) | Соединение | |
| ES2690341T3 (es) | Derivados de 2-amino-5-trifluorometil-pirimidina y su uso como inhibidores de la quinasa PTK2 | |
| JP2019524883A5 (enExample) | ||
| KR102150383B1 (ko) | 안지오텐신 ii 수용체 길항제 대사물질과 nep 억제제의 화합물, 및 이의 제조 방법 | |
| JP2016512531A5 (enExample) | ||
| JP2015532295A5 (enExample) | ||
| JP2022502500A5 (enExample) | ||
| JP2015510916A5 (enExample) | ||
| RU2015110699A (ru) | Фармацевтическая антиретровирусная композиция | |
| JP7445597B2 (ja) | キノロン類似体及びそれらの塩、組成物、ならびにそれらの使用方法 | |
| JP2016510326A5 (enExample) | ||
| US20100260750A1 (en) | Novel serotonin reuptake inhibitors as drugs having peripheral-system-restricted activity | |
| JP2015521191A5 (enExample) | ||
| FI3737470T3 (fi) | 3-fenyyli-4-heksyylihappojohdannaisia GPR40-agonisteina | |
| JP2016530238A5 (enExample) | ||
| JP2016514688A5 (enExample) | ||
| EA033291B1 (ru) | Единица дозирования, содержащая рамиприл и бисопролола гемифумарат, способ ее получения и способ лечения гипертензии | |
| RU2015129714A (ru) | Композиция в форме таблеток, содержащая гидрохлорид цинакалцета | |
| JP2020502106A5 (enExample) | ||
| JP2017517574A5 (enExample) | ||
| HUE071451T2 (hu) | Vegyület, gyógyászatilag elfogadható sója vagy optikai izomere, eljárás elõállítására és hatóanyagként azt tartalmazó, vírusos betegség megelõzésére vagy kezelésére szolgáló gyógyászati készítmény | |
| JP2020506886A5 (enExample) | ||
| US9278947B2 (en) | Serotonin reuptake inhibitors as drugs having peripheral-system-restricted activity | |
| WO2009000907A2 (en) | Combination of picotamide with nafronyl |